CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 829 enrolled
Drug / intervention
Herpes Zoster vaccine GSK 1437173A +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01954251
NCT01954251Phase 3Completed
CompareCT.gov

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

GlaxoSmithKline·interventional·Posted Oct 1, 2013·Updated May 2, 2018

In Brief

A Phase 3 clinical trial evaluating Herpes Zoster vaccine GSK 1437173A and GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A for Herpes Zoster. Completed, enrolled 829 participants across 20 sites in 3 countries.

Detailed Summary

The purpose of this study is to assess immunogenicity, reactogenicity and safety of GSK Biologicals' HZ/su vaccine when its first dose is co-administered with the FLU-D-QIV vaccine in adults aged 50 years or older compared to administration of vaccines separately.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHerpes Zoster
CountriesCanada, Germany, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 1, 2013
Enrollment StartOct 3, 2013
Primary CompletionJun 2, 2014
Study CompletionMar 20, 2015
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 12.8 years ago

Interventions

Herpes Zoster vaccine GSK 1437173Abiological

2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.

GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138Abiological

2 doses administered intramuscularly (IM) in the deltoid region of the dominant arm.